-
Dr Vincent Wong: Lean metabolic associated fatty liver disease from a clinical perspective
The Combined GlHep&SHC 2024 will be held in Singapore from July 25th to 28th, 2024. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Hepatology Digest invited Dr Vincent Wong from The Chinese University of Hong Kong…
-
Dr Lim Seng Gee: Looking forward to the emergence of new treatment methods for MAFLD in the future
Recently, the Combined GlHep&SHC 2024 was held in Singapore. This conference covers various aspects of liver disease research and provides an interdisciplinary communication platform for experts and scholars. During the conference, Hepatology Digest conducted an exclusive interview with Professor Lim Seng Gee from the National University Hospital of Singapore, asking him to introduce the current…
-
Continuing the Miracle of Healing, Interview with Dr. Christian Gaebler, Speaker of “The Next Berlin Patient” | AIDS 2024
At the just concluded 25th International Conference on AIDS (AIDS2024), as a major clinical research progress of the conference, Dr. Christian Gaebler of Charlotte University in Berlin, Germany, reported the seventh “next Berlin patient” to be cured after the world’s first “Berlin patient” cured of HIV. This patient did not follow the traditional path of…
-
AIDS Interview | New Breakthrough of Broad Spectrum Neutralizing Antibodies (bnAbs) in HIV Prevention and Treatment
Broad spectrum neutralizing antibodies (bnAbs) are showing unprecedented potential in the field of HIV prevention and treatment. At the 25th International AIDS Conference (AIDS2024), Professor Hyman Scott, medical director of Bridge HIV clinical research, San Francisco Department of Public Health, introduced the latest progress of bnAbs in HIV prevention and treatment. Infectious Disease Frontier（IIDF） is…
-
2024 CUDA丨Dr. Kan Gong: Addressing Clinical Needs in mHSPC and Bringing More Benefits to Patients Through Novel Endocrine Therapies
In the stage of metastatic hormone-sensitive prostate cancer (mHSPC), effective treatment is crucial to delaying the progression to castration-resistant stages (mCRPC), thereby extending patient survival. From August 8-11, 2024, the Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association (CUDA) was grandly held in Xi’an, Shaanxi Province. At the conference, Dr.…
-
WCLC Returns to North America, IASLC to Celebrate 50 Years of International Collaboration in Thoracic Oncology at 2024 WCLC
In 1974, David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain, and George Higgins recruited over 250 founding members from around the world and organized the first meeting of the International Association for the Study of Lung Cancer (IASLC) in Florence, Italy. Fifty years later, the field of lung cancer has seen countless scientific…
-
2024 CUDA丨Dr. Zhisong He: China’s Leading Role in Kidney Cancer Surgical Techniques and the National Quality Control Program Enhancing Treatment Standards at the 2024 CUDA Annual Meeting
Kidney cancer is one of the three most common urological tumors in China, with an increasing incidence rate in recent years. As surgical techniques and new treatment strategies for kidney cancer have advanced, patient survival rates have also improved. At the 2024 Annual Meeting of the Urological Surgeon Branch of the Chinese Medical Doctor Association…
-
2024 CUDA丨Dr. Hailong Hu: Exploring Greater Benefits for NMIBC Patients Through Advances in Novel Therapies
Non-muscle-invasive bladder cancer (NMIBC) accounts for over 70% of all bladder cancer cases. For NMIBC patients, the primary treatment goals are to eliminate tumor cells, prevent recurrence and progression, while preserving bladder function and quality of life as much as possible. From August 8-11, 2024, the Annual Meeting of the Urological Surgeon Branch of the…
Connecting Medical Expertise through Media